Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (3673)	12/15/1997 12:34:00 AM
From: Cacaito	Respond to of 23519

It does look like a profit, vinik probably unloaded the day of the FDA and UK approval, the second one there was not even a move up and accumulation was ongoing very mildly (mainly small investors, I was thinking of taking more, I stop to pay more of my credit cards). so even if he loss money in the second unloading time, he have a nice tax loss to pair with, not a huge one. About that time his holdings came down to less than 5% so no more reporting of his moves were necessary. Now, he could accumulate back if he knows the full story for even a bigger profit. If he knows the complete story then he will not be back at all. Vinik, vini, vidi, vinci. Bigger than Caesar.

To: blankmind who wrote (3673)	12/15/1997 12:43:00 AM
From: Zebra 365	Respond to of 23519

Vinik reported sales down to 4.8% ownership, at which point he no longer had to report sales publicly. No one knows by public reports if Vinik still has the 4.8% or any other amount under 5.0%. Cacatio, Muse has been approved for sale since November 19, 1996. The 100 million in sales is for Nine Months, not a year. TO ALL: So the company didn't warn anyone about production being a potential problem? From the 10Q for March 31, 1997 RISK FACTORS LIMITED MANUFACTURING EXPERIENCE AND DEPENDENCE ON SOLE CONTRACT MANUFACTURER The Company has only limited experience in manufacturing MUSE (alprostadil) in commercial quantities. Since the commercial launch of its product in January 1997, the Company has experienced product shortages due to higher than expected demand. If the Company encounters any manufacturing difficulties, including problems involving production yields, quality control and assurance, supplies of components or raw materials or shortages of qualified personnel, it could have a material adverse effect on the Company's business, financial condition and results of operations. The formulation, filling, packaging and testing of MUSE (alprostadil) is performed by Paco Pharmaceutical Services, Inc. ("Paco"), a wholly owned subsidiary of The West Company, at its facility in Lakewood, New Jersey. In June 1995, the Company completed construction of its approximately 6,000 square feet manufacturing and testing space within Paco's facility. Due to higher than expected demand, the Company has leased two adjacent buildings in New Jersey, totaling 90,000 square feet, that will be built out to support expansion of the Company's manufacturing capabilities. Until the Company develops an in-house manufacturing capability, it will be entirely dependent upon Paco for the manufacture of its products. There can be no assurance that the Company's reliance on Paco for the manufacture of its products will not result in problems with product supply, and there can be no assurance that the Company will be able to establish a second manufacturing facility. Interruptions in the availability of products could delay or prevent the development and commercial marketing of MUSE (alprostadil) and other potential products and would have a material adverse effect on the Company's business, financial condition and results of operations. ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Folks this was issued by the company nine months ago. I love investing in the market because I'm never wrong. If the stock goes up, I was smart for picking it. If a stock goes down, its because of "market-makers" or "crooked management". Yes, I can see it now, the whole developmment of MUSE and 100 million in sales in the first nine months of sales was just to lure me in to buying this stock. But, wait a minute, I didn't buy it from the company, so how do they benefit from deceiving me? Ahhh, the stock repurchase, now they can buy cheaper. This is so clever, the trilateral comission must be behind it. Next post Zebra exposes how the largest trial of an ED drug was rigged to show the drug works. Zebra

To: blankmind who wrote (3673)	12/15/1997 1:48:00 AM
From: Milan	Respond to of 23519

Vinik, Jeffrey N., VGH Partners, L.L.C., Vinik Partners, L.P., Vinik Asset Management, L.P., Gordon, Michael S. of , Files SEC FORM 13D WASHINGTON, DC, Nov. 18, 1997 (States) -- Item 5. Interest in Securities of the Issuer: Reports that Between 09-15-97 and 10-28-97, the Reporting Persons, led by Jeffrey N. Vinik, acquired 35, 000 common shares of the Issuer, Vivus, Inc., for $24.52 to $27.625 per share. Between 09-24-97 and 11-04-97, the Reporting Persons sold 843, 500 Issuer common shares for $25.1749 to $40.7373 per share. ISSUER: Vivus Inc. of Alberta, Calgary SHARES OWNED: 1603600 PERCENTAGE OWNED: 4.80 SEC DATE: 11/18/97 FILING DATE: 11/04/97 EVENT DATE: 11/03/97 -0-